Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case
Provided By PR Newswire
Last update: Feb 21, 2023
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023.
Read more at prnewswire.com5.43
-0.01 (-0.18%)
Find more stocks in the Stock Screener
SCLX Latest News and Analysis
14 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
